Abstract
In large part cellular dysfunctions induced by chronic hyperglycemia are similar in type-1 and -2 diabetes. In both instances chronic hyperglycemia induces injury to a multitude of organs by affecting various target cells. The cells affected may include those derived from of epithelial or mesenchymal progenitors; and at times hyperglycemia may induce phenotypic changes with epithelial-mesenchymal transformation. In the majority of target cells the high-glucose ambience activates various intracellular pathways that are similar except for minor exceptions that are related to the selective expression of various molecules in a given cell type. Keeping in perspective a common paradigm applicable to most of the cells, a brief discussion of different hyperglycemia-induced cellular events pertaining to various pathways is described in this review. They include fluxes of glucose intermediaries in various cellular metabolic pathways, generation of advanced glycation end products (AGEs) and their extra- and intracellular effects, the role of protein kinase C, transforming growth factor-β, guanosine triphosphate-binding proteins and reactive oxygen species (ROS) in various cellular signaling events. The latter, i.e., ROS, may be central to several intracellular pathways and modulate various events in a reciprocal manner. The information compiled under various subtitles of this synopsis is derived from an enormous amount of literature data summarized in several recent excellent reviews, and thus further reading of them is suggested to gather detailed comprehensive information on each of the subjects.
Journal Section:
Minireview
References
1.
LeRoith D, Taylor SI and Olefsky JM: Diabetes mellitus: A Fundamental and Clinical Text, ed 3. Philadelphia, Lippincott William & Wilkins, 2004, pp 1–1540.
2.
Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2000;414:813–820.
3.
Sheetz MJ, King GL: Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA 2002;288:2579–2588.
4.
Chugh SS, Wallner EI, Kanwar YS: Renal development in high-glucose ambience and diabetic embryopathy. Semin Nephrol 2003;23:583–592.
5.
Reddy AS: Diabetic Nephropathy: Theory and Practice. East Hanover, College Book Publishers, 2004, pp 1–563.
6.
Parving H-H, Osterby R, Ritz E: Diabetic nephropathy; in Brenner BM (ed): The Kidney. Philadelphia, Saunders, 2000, pp 1731–1773.
7.
Mason RM, Wahab NA: Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003;14:1358–1373.
[PubMed]
8.
Heilig CW, Brosius FC, Henry DN: Glucose transporters of the glomerulus and the implications for diabetic nephropathy. Kidney Int 1997;60:S91–S99.
9.
Nelson DL, Cox MM: Glycolysis and catabolism of hexoses; The citric acid cycle. Lehninger Principles of Biochemistry. New York, Worth, 2000, pp 527–597.
10.
Schleicher ED, Weigert C: Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int 2000;58(suppl 77):S13–S18.
11.
Chung SS, Ho EC, Lam KS, Chung SK: Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 2003;14(suppl 3):S233–S236.
12.
Arner RJ, Prabhu KS, Thompson JT, Hildenbrandt GR, Linken AD, Reddy CC: Myo-inositol oxygenase: Molecular cloning and expression of a unique enzyme that oxidizes myo-inositol and D-chiro-inositol. Biochem J 2001;300:313–320.
13.
Yang Q, Dixit B, Wada J, Tian Y, Wallner EI, Srivastva SK, Kanwar YS: Identification of a renal-specific oxido-reductase in newborn diabetic mice. Proc Natl Acad Sci USA 2000;97:9896–9901.
14.
Greene DA, Lattimer SA, Sima AA: Sorbitol, phosphoinositides, and Na+/K+ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987;316:599–606.
[PubMed]
15.
Greene DA, Lattimer SA, Sima AA: Are disturbances of sorbitol, phosphoinositide, and Na+/K+ATPase regulation involved in pathogenesis of diabetic neuropathy. Diabetes 1988;37:688–693.
[PubMed]
16.
Ziyadeh FN, Simmons DA, Snipes ER, Goldfarb S: Effect of myoinositol on cell proliferation and collagen transcription and secretion in proximal cells cultured in elevated glucose. J Am Soc Nephrol 1991;1:1220–1229.
[PubMed]
17.
Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223–234.
18.
Schleicher ED, Bierhaus A, Haring HU, Nawroth PP, Lehmann R: Chemistry and pathobiology of advanced glycation end products; in D’Angelo A, Favaro S, Gambaro G (eds): Advanced Glycation End Products in Nephrology. Contrib Nephrol. Basel, Karger, 2001, vol 131, pp 1–9.
19.
Sakurai S, Yonekura H, Yamamoto Y, Watanabe T, Tanaka N, Li H, Rahman AK, Myint KM, Kim CH, Yamamoto H: The AGE-RAGE system and diabetic nephropathy. J Am Soc Nephrol 2003;14(suppl 3):S259–S263.
20.
Jakus V, Rietbrock N: Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004;53:131–142.
[PubMed]
21.
Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME, Forbes JM: Attenuation of extracellular matrix accumulation in diabetic nephropathy by advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-α-dependent pathway. Diabetes 2004;53:2921–2930.
[PubMed]
22.
Forbes JM, Cooper ME, Oldfield MD, Thomas MC: Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003;14(suppl 3):S254–S258.
23.
Whiteside CI, Dlugosz JA: Mesangial cell protein kinase C isozyme activation in diabetic milieu. Am J Physiol Renal Physiol 2002;282:F975–F980.
24.
Parker PJ, Murray-Rust J: PKC at a glance. J Cell Sci 2004;117:131–132.
25.
Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, Sato N, Sekiguchi N, Kobayashi K, Sumimoto H, Utsumi H, Nawata H: Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003;14(suppl 3):S227–S232.
26.
Leask A, Abraham DJ: TGF-β signaling and the fibrotic response. FASEB J 2004;18:816–827.
27.
Schiffer M, von Gersdorf G, Bitzer M, Susztak K, Bottinger EP: Smad proteins and transforming growth factor-β signaling. Kidney Int 2000;58(suppl 77):S45–S52.
28.
Ziyadeh FN: Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 2004;15(suppl 1):S55–S57.
29.
Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999;274:5830–5834.
30.
Takai Y, Sasaki T, Matozaki T: Small GTP-binding proteins. Physiol Rev 2001;81:153–208.
[PubMed]
31.
Kim SL, Kim HJ, Han DC, Lee HB: Effect of lovastatin on small GTP binding proteins and TGF-β1 and fibronectin expression. Kidney Int 2000;58(suppl 77):S88–S92.
32.
Sharpe CC, Hendry BM: Signaling: Focus on Rho in renal disease. J Am Soc Nephrol 2003;14:261–264.
33.
Lin S, Sahai A, Chugh SS, Pan X, Wallner EI, Danesh FR, Lomasney JW, Kanwar YS: High glucose stimulates synthesis of fibronectin via a novel protein kinase C, Rap1b and B-Raf signaling pathway. J Biol Chem 2002;277:41725–41735.
34.
Lin S, Chugh SS, Pan X, Wallner EI, Wada J, Kanwar YS: Identification of up-regulated Ras-like GTPase, Rap1b, by suppression subtractive hybridization. Kidney Int 2001;60:2129–2141.
35.
Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS: HMG-CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci USA 2002;99:8301–8305.
36.
Zeng L, Xu H, Chew T-L, Chisholm R, Sadeghi MM, Kanwar YS, Danesh FR: Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27. J Am Soc Nephrol 2004;15:1711–1720.
37.
Wolf G: Molecular mechanism of diabetic mesangial cell hypertrophy: a proliferation of novel factors. J Am Soc Nephrol 2002;13:2611–2613.
[PubMed]
38.
Werner E: GTPases and reactive oxygen species: switches for killing and signaling. J Cell Sci 2004;117:143–153.
39.
Djordjevic VB: Free radicals in cell biology. Int Rev Cytol 2004;237:57–89.
[PubMed]
40.
Radi R, Cassina A, Hodara R, Quijano C, Castro L: Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med 2002;33:1451–1464.
41.
Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M: Effects of antioxidants in diabetes-induced oxidative stress in glomeruli of diabetic rats. J Am Soc Nephrol 2003;14(suppl 3):S250–S253.
42.
Li JM, Shah AM: ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol 2003;14(suppl 3):S221–S226.
43.
Kang D, Hamasaki N: Mitochondrial oxidative stress and mitochondrial DNA. Clin Chem Lab Med 2003;41:1281–1288.
44.
Schrauwen P, Hesselink MK: Oxidative capacity, lipotoxicity and mitochondrial damage in type 2 diabetes. Diabetes 2004;53:1412–1417.
[PubMed]
45.
Lee HB, Yu MI-RA, Yang Y, Jiang Z, Ha H: Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003;14(suppl 3):S241–S245.
46.
Phillips AO: The role of renal proximal tubular cells in diabetic nephropathy. Curr Diab Rep 2003;3:491–496.
[PubMed]
47.
Maassen JA, Hart LM, Van Essen E, Heine RJ, Nijpels G, Jahangir RS, Raap AK, Janssen GM, Lemkes HH: Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes 2004;53(suppl 1):S103–S109.
48.
Kiritoshi S, Nishikawa T, Sonoda K, Kukidome D, Senokuchi T, Matsuo T, Matsumura T, Tokunaga H, Brownlee M, Araki E: Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells. Diabetes 2003;52:2570–2577.
[PubMed]
49.
Carven RP, Melhem MF, Phillips SL, De Rubertis FR: Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 2001;50:2114–2125.
[PubMed]
50.
DeRubertis FR, Craven PA, Melhem MF, Salah EM: Attenuation of renal injury in db/db mice overexpressing superoxide dismutase: Evidence for reduced superoxide-nitric oxide interaction. Diabetes 2004;53:762–768.
[PubMed]
51.
Vasquez-Vivar J, Kalyanaraman B, Martasek P: The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic Res 2003;37:121–127.
52.
Scott-Burden T: Regulation of nitric oxide production by tetrahydropterin. Circulation 1995;91:248–250.
[PubMed]
53.
Cosentino F, Katusic Z: Tetrahydrobiopterin and dysfunction of the endothelial nitric oxide synthase in coronary arteries. Circulation 1995;91:139–144.
[PubMed]
54.
Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Circ Res 2000;87:840–844.
55.
Pieper GM: Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol 1997;29:8–15.
56.
Wallace DC: Mitochondrial diseases in man and mouse. Science 1999;283:1482–1428.
© 2005 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2005
You do not currently have access to this content.
